HER2: Closing the gap between laboratory testing and clinical practice

American Journal of Clinical Pathology

Volumn 131, Issue 6, 2009, Pages 897-898

  Plebani, Mario ^a   Lippi, Giuseppe ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; CANCER RELAPSE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LETTER; MEDICAL DECISION MAKING; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TISSUE FIXATION;

BREAST NEOPLASMS; FEMALE; HUMANS; LABORATORIES; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, ERBB-2;

EID: 67149101028     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP1VQ9LOBOIMHO     Document Type: Letter

References (9)

1. Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129:263-273.
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
3. Bartlett JMS, Ibrahim M, Jasani B, et al. External quality assurance of HER2 FISH and ISH testing: three years of the UK National External Quality Assurance Scheme. Am J Clin Pathol. 2009;131:106-111.
4. Plebani M, Marincola FM. Research translation: a new frontier for clinical laboratories. Clin Chem Lab Med. 2006;44:1303-1312.
5. Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008;113:1294-1301.
6. Schippinger W, Dandachi N, Regitnig P, et al. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer. Am J Clin Pathol. 2007;128:630-637.
7. Lüftner D, Cheli C, Mickelson K, et al. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers. 2004;19:175-182
8. Yeh IT. Measuring HER-2 in breast cancer. Immunohistochemistry, FISH, or ELISA? Am J Clin Pathol. 2002;117(suppl):S26-S35.
9. Olsen DA, Østergaard B, Bokmand S, et al. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med. 2007;45:177-182.